

Resource Summary Report

Generated by [dkNET](#) on Aug 12, 2026

InVivoMab anti-human CD3

RRID:AB_1107632

Type: Antibody

Proper Citation

(Bio X Cell Cat# BE0001-2, RRID:AB_1107632)

Antibody Information

URL: http://antibodyregistry.org/AB_1107632

Proper Citation: (Bio X Cell Cat# BE0001-2, RRID:AB_1107632)

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: in vitro Organoids/Organ-on-Chip

Antibody Name: InVivoMab anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: clone OKT-3

Antibody ID: AB_1107632

Vendor: Bio X Cell

Catalog Number: BE0001-2

Alternative Catalog Numbers: BE0001-2-50MG, BE0001-2-100MG, BE0001-2-1MG, BE0001-2-25MG, BE0001-2-5MG

Record Creation Time: 20260114T193410+0000

Record Last Update: 20260706T190415+0000

Ratings and Alerts

No rating or validation information has been found for InVivoMab anti-human CD3.

No alerts have been found for InVivoMab anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 34 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Sun JL, et al. (2026) Ferroptotic tumor cells reprogram tumor-associated macrophage antigen presentation to enhance the efficacy of immune checkpoint blockade. *Cell reports. Medicine*, 7(5), 102774.

Rush JS, et al. (2026) Human genetics guides the discovery of CARD9 inhibitors with anti-inflammatory activity. *Cell*, 189(5), 1356.

Katko A, et al. (2026) Gene regulatory network determinants of rapid recall in human memory CD4+ T cells. *Cell reports*, 45(4), 117103.

Zhou J, et al. (2026) Gut microbiota-derived indole-3-lactic acid suppresses anti-PD-1 efficacy in esophageal squamous cell carcinoma. *Cell host & microbe*, 34(4), 639.

Chen S, et al. (2026) Targeting KIF20A blocks lactylation modification to suppress immune escape in hepatocellular carcinoma. *iScience*, 29(4), 115372.

Xie H, et al. (2025) Lymphotoxin-driven cancer cell eradication by tumoricidal CD8+ TIL. *bioRxiv : the preprint server for biology*.

Rahman J, et al. (2025) A CD4+ T cell-intrinsic complement C5aR2-prostacyclin-IL-1R2 axis orchestrates Th1 cell contraction. *Immunity*, 58(6), 1438.

Allard D, et al. (2025) Adenosine Uptake through the Nucleoside Transporter ENT1 Suppresses Antitumor Immunity and T-cell Pyrimidine Synthesis. *Cancer research*, 85(4), 692.

Lim YJ, et al. (2024) MicroRNA-19b exacerbates systemic sclerosis through promoting Th9 cells. *Cell reports*, 43(8), 114565.

Du X, et al. (2024) Regulation of the Function of T Follicular Helper Cells and B Cells in Type 1 Diabetes Mellitus by the OX40/OX40L Axis. *The Journal of clinical endocrinology and metabolism*, 109(11), 2823.

Scott KA, et al. (2024) Covalent targeting of splicing in T cells. *Cell chemical biology*.

Chen C, et al. (2024) Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8+ T cell exhaustion and anti-PD-1 resistance. *Cell reports. Medicine*, 5(8), 101686.

Liu Y, et al. (2024) IL-21-armored B7H3 CAR-iNKT cells exert potent antitumor effects. *iScience*, 27(1), 108597.

Zwijnenburg AJ, et al. (2023) Graded expression of the chemokine receptor CX3CR1 marks differentiation states of human and murine T cells and enables cross-species interpretation. *Immunity*, 56(8), 1955.

West EE, et al. (2023) Loss of CD4+ T cell-intrinsic arginase 1 accelerates Th1 response kinetics and reduces lung pathology during influenza infection. *Immunity*, 56(9), 2036.

Hadley P, et al. (2023) Precise surface functionalization of PLGA particles for human T cell modulation. *Nature protocols*, 18(11), 3289.

Pei S, et al. (2023) A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy. *Cancer discovery*, 13(9), 2032.

Gbyli R, et al. (2022) In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2. *Leukemia*, 36(5), 1313.

Hernández-Malmierca P, et al. (2022) Antigen presentation safeguards the integrity of the hematopoietic stem cell pool. *Cell stem cell*, 29(5), 760.

Rossignol J, et al. (2022) Neuropilin-1 cooperates with PD-1 in CD8+ T cells predicting outcomes in melanoma patients treated with anti-PD1. *iScience*, 25(6), 104353.